Instil Bio Inc. and ImmuneOnco Biopharmaceuticals have announced updates regarding the clinical trials of their bispecific antibody, '2510, for the treatment of non-small cell lung cancer (NSCLC). The companies revealed that a Phase 3 trial of '2510 in combination with chemotherapy for first-line NSCLC is anticipated to commence in mid-2026 in China, contingent upon regulatory discussions. Meanwhile, a U.S. monotherapy dose optimization Phase 1b/2 trial for relapsed/refractory solid tumors is expected to start before the end of 2025, pending regulatory approvals. This trial aims to align the dosing with ongoing trials in China and replaces a previously planned U.S. trial combining '2510 with chemotherapy for first-line NSCLC. Furthermore, ImmuneOnco plans to share initial safety and efficacy results from a Phase 2 trial in China during the second half of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.